Connections The Newsletter for the University of Kansas Alzheimer’s Disease Center
Summer / Fall 2014
Inside This Issue - 1-2 Is weight loss an early warning sign of Alzheimer’s
Is weight loss an early warning sign of Alzheimer’s? By Anne Harding, Health.com via CNN.com
-3Studies at a Glance -4KU Clinical Research Center Grand Opening Volunteering with the KU ADC -5KUMC named inaugural member of NIH’s NeuroNEXT clinical trials network -62011-2012 Pilot Grant Recipients -7Redefining the Baby Boom Generation? -8ADC News -9Caregiver’s Corner
R
esearchers say there is a possibility that weight loss or a low body mass index (BMI) later in life may be an early warning sign of mental decline. The following is a story carried nationally by CNN.com featuring our local KU ADC research. STORY HIGHLIGHTS • A new study may offer a clue to the relationship body weight and Alzheimer’s disease • Jeffrey M. Burns, M.D., says Alzheimer’s Disease may trigger changes that promote weight loss • The goal of the study is to find ways to measure the progression of Alzheimer’s Disease
(Health.com) -- Over the past several years, researchers have noticed an odd pattern in the relationship between body weight and Alzheimer’s disease: Middle-aged people have a higher long-term risk of developing the disease if they’re overweight or obese, while older people have a lower risk of the disease if they’re carrying excess weight. A new study, published in the journal Neurology, may offer a clue to this so-called obesity paradox. Non-overweight individuals in their late 60s, 70s, and early 80s who have no outward symptoms of Alzheimer’s Disease are more likely than their heavier peers to have biological markers (or biomarkers) of the disease, the study found. This finding raises the possibility that weight loss or a low body mass index (BMI) later in life may be an early warning sign of mental decline, the
Continued on page 2
Continued from page 1
researchers say. “Weight changes or body composition changes may actually be a manifestation of disease, which would explain the obesity being an apparent protective factor later in life,” says Eric Vidoni, PT, PhD, the lead author and Assistant Director of the University of Kansas Alzheimer’s Disease Center in Kansas City. Well before memory loss and other symptoms appear, Alzheimer’s disease may trigger metabolism changes that promote weight loss, Vidoni says. “In general, we think of Alzheimer’s disease as a brain disease, but this is evidence that there are systemic problems throughout the body in the early stages of Alzheimer’s disease.” Burns, Vidoni and colleagues analyzed data from the Alzheimer’s disease Neuroimaging Initiative, a huge study that the KU ADC is part of, spanning 58 hospitals and universities that’s funded by the National Institutes of Health and an array of nonprofit organizations and drug companies. The goal of the initiative is to find ways to measure the progression of Alzheimer’s disease and the precursor condition known as mild cognitive impairment. The researchers looked at 101 people who underwent brain scans designed to identify the plaques and abnormal tangle of proteins that are the hallmark of Alzheimer’s disease and another 405 people whose cerebrospinal fluid was analyzed for fragments of these
proteins (beta-amyloid peptide and tau). Each group included some people with Alzheimer’s disease, some with mild cognitive impairment, and some with no signs of mental deterioration. There was no connection between BMI and Alzheimer’s disease biomarkers in the patients who actually had Alzheimer’s disease. But in the other two groups, lower BMI was associated with higher levels of biomarkers and a higher likelihood of having brain plaques and tangles. Among people with mild cognitive impairment, for instance, 85 percent of non-overweight individuals had signs of these brain abnormalities, compared to just 48 percent of those who were overweight or obese. (A BMI of 25 or above is considered overweight.) Richard Lipton, M.D., an attending neurologist at Montefiore Medical Center, in New York City, who was not involved in the new research, agrees with the authors that the findings suggest that Alzheimer’s disease can affect the entire body early on. “The most obvious manifestations of Alzheimer’s disease are in the brain, but Alzheimer’s disease has a large number of effects on the body as well,” says Lipton, the principal investigator of a long-running study on aging and Alzheimer’s. “The brain regulates blood pressure and respiratory rate and pulse and hunger and satiety and blood flow to various organs in the body, so it wouldn’t be surprising if a widespread disease of the brain
2
had effects on many, many different aspects of bodily function.” The study shows only an association, not cause and effect, so Burns and his colleagues can’t be sure that Alzheimer’s disease directly causes weight loss (or prevents weight gain). In fact, the researchers found no association between BMI changes and Alzheimer’s disease biomarkers in a subset of study participants whose weight was tracked for two years. May Ahmad Baydoun, Ph.D., a staff scientist at the National Institute on Aging who studies risk factors for dementia, described the study as “very strong” overall. But, she says, “the results would have been a lot stronger if they found weight loss over time is associated with increased Alzheimer’s disease pathology, also over time.” The relationship between weight loss and the progression of Alzheimer’s disease is likely a two-way street, Lipton says. People who start to experience declines in mental function may shop for groceries less regularly, cook less frequently, and eat less -- and the poor nutrition that results could in turn accelerate the progression of the disease, he says. “It seems pretty likely to me that both things are true -- that good health practices prevent illness, and health practices may fall apart in the early stages of illness and accelerate cognitive and physical decline,” Lipton says.
You Can Help! Are you, or do you know someone, interested in participating in Alzheimer’s research?
STUDIES AT A GLANCE Study Name
Trial of Exercise on Aging and Memory (TEAM)
Alzheimer’s Disease Exercise Program Trial (ADEPT)
ADNI 2
SPA
ADC Program Registry
Number Enrolled
79
30
5
11
184
Target Enrollment
Criteria
100
65 years and older, not currently exercising
This is a year-long study evaluating how exercise may improve thinking and memory in healthy, older adults with no memory problem.
80
55 years and older, mild to moderate AD, not currently exercising
This is a 6 month study to evaluate the effect of aerobic exercise on memory and thinking skills.
Description
14
This study is using information gathered 65 and older, with and from brain imaging and biomarkers without memory to better understand aging and Alzheimer’s disease. problems
20
55 and older with a diagnosis of AD
This study is testing the safety and tolerability of R-Pramepexole for use in those with Alzheimer’s disease
400
65 and older without memory problems, 55 and older with memory problems
Participants in this study will complete three annual assessments as part of the KU ADC, including an annual memory and thinking assessment with a clinician, cognitive testing, physical functioning testing, and lab draws.
For more information, or to see if you would qualify for one of these studies, please call the KU Alzheimer & Memory Research Line at 913-588-0555. 3
The KU Clinical Research Center Grand Opening
T
he KU Clinical Research Center, which is the new home of the KU Alzheimer’s Disease Center, held its public grand opening in March. Leaders from across the Kansas City community and the University of Kansas toured the
facility. The grand opening was also featured in the Kansas City Star, which interviewed a KU ADC study participant about their experience with the new facility.
Interested in Volunteering with the KU ADC? Become a KU ADC Ambassador per year. Whether it’s greeting potential study subjects, assisting with projects, or volunteering at events, we will find a project that suits your time commitment and abilities.
The KU ADC is seeking study participants and study partners from past or current programs to serve as KU ADC Ambassadors. These program ambassadors would help us share information with the community about the work of the KU ADC, the benefits to participating in our research, and serve as our partners to growing our program in Kansas City and beyond.
2. Help us find two speaking engagements within the community; through religious or civic organizations, corporate events, or small group gatherings, we are happy to share our information with your audience. 3. Tell three people about the KU ADC and our research opportunities. If interested, please visit our website (www.kualzheimer. org) or call at 913-588-0555 x1; we will then send you a brief application for the program and additional information. Ambassadors would complete a brief online training to review some basic facts about the program, healthy brain aging, and Alzheimer’s disease. Ambassadors would also receive invitations to exclusive, ADC-Ambassador only educational programming and events with ADC researchers and clinicians as a thank-you for their commitment to our program.
Serving as an ADC Ambassador is as easy as 1-2-3! All KU ADC Ambassadors would be asked to provide: 1. One day (eight hours) of volunteer time to the KU ADC 4
KUMC named inaugural member of NIH’s NeuroNEXT clinical trials network
T
he University of Kansas Medical Center has been selected as one of just 25 sites nationwide to participate in the newly created Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT), a federally funded group of research institutions that will work to speed up the development of new treatments for neurological disorders. Funded by a seven-year $2.1 million grant from the National Institute of Neurological Disorders and Stroke at the National Institutes of Health, KUMC will work with institutions nationwide to test new medications and treatments in diverse populations around the country. KUMC will also partner locally with the pediatric neurology department at Children’s Mercy Hospital and with KU’s Life Span Institute and Child Development Center on the Lawrence campus.
“Once again, the National Institutes of Health is recognizing the excellence of our research by selecting our scientists to take part in a national effort to speed the development of cures for diseases of the brain and nerves,” said Barbara Atkinson, MD, Former Executive Vice Chancellor of the University of Kansas Medical Center. This award adds to KUMC’s recent string of success in raising its national research prominence. In June 2011, KUMC joined an elite group of 60 universities when the NIH awarded it a $20 million Clinical and Translational Science Award. In August, KUMC was awarded a $6 million grant designating it as an Alzheimer’s Disease Center, one of just 29 institutions in the country. “Becoming part of the NeuroNEXT network demonstrates that our investigators are national leaders in neurological research,” Atkinson said.
“We have patients in the region who are committed to participating in national studies that will lead us to better treatments for neurological disorders,” said Richard J. Barohn, MD, Chair of the KUMC Department of Neurology and director of KUMC’s NeuroNEXT research group, the Heartland Unit for Neuroscience Trials (HUNT). “The Heartland Unit for Neuroscience Trials will collaborate with local and national scientists to bring leading-edge clinical trials to Kansas City,” said Jeffrey Burns, MD, co-director of the program. “Our goal is to speed the development of effective therapies for diseases of the nervous system.” Some trials will take place in KU’s new Clinical Research Center in Fairway, created specifically to house early phase clinical trials, which opened earlier this year.
The NeuroNEXT network is designed to increase the efficiency and quality of neuroscience clinical trials, to recruit and retain patients for such trials, and to encourage public-private partnerships in the pursuit of cures and treatments. Chosen for their clinical trials expertise and available patient populations, the NeuroNEXT sites were announced on October 3. • Albert Einstein College of Medicine Yeshiva University
• University of California - Davis
• Children’s Hospital - Boston
• University of Cincinnati
• University of California - Los Angeles
• Children’s National Medical Center
• University of Colorado - Denver
• Columbia University - Weill Cornell
• University of Kansas Medical Center
• Emory University
• University of Miami School of Medicine
• Massachusetts General Hospital
• University of Pittsburgh
• Northwestern University
• University of Rochester
• Ohio State University
• University of Texas Southwestern Medical Center
• Oregon Health and Science University
• University of Utah
• SUNY (Buffalo, Downstate, Upstate, and Stony Brook)
• University of Virginia - Charlottesville • Vanderbilt University
• Swedish Health Services - Seattle
• Washington University in St. Louis School of Medicine
• University of Alabama at Birmingham
5
2014-2015 Pilot Grant Recipients
T
he University of Kansas Alzheimer’s Disease Center is pleased to announce the 2011-2012 Pilot Project Program awardees. The KU ADC, along with the support of the Landon Center on Aging, will fund 4 research projects that have been judged to have significant potential for impact in their field and translation to external funding. Twenty exceptional projects were submitted in response to this inaugural request for applications. Below are excerpts from the 4 funded projects.
Janna Harris, PhD and William Brooks PhD – KUMC Hoglund Brain Imaging Center
Gang Hu, PhD – KU Higuchi Bioscience Center In this study, we will identify the role of amyloid binding alcohol dehydrogenate (ABAD) and amyloid in changing lipid and fatty acid metabolism in Alzheimer’s disease and show for the first time that there is a link between mechanisms that influence the function of mitochondria (i.e. increases in ABAD and Aβ) and changes in lipid metabolism. We will identify how they are linked and identified a new phenomenon that occurs within mitochondria and is potentially controlled by the binding of Aβ to ABAD. Specifically, we will identify the role of ABAD in Aβ-mediated changes in lipid metabolism relevant to the pathogenesis of AD using novel transgenic mice to determine the effect of ABAD on Aβ-induced lipid metabolism. The outcomes of this project will have a significant impact on the AD research field, in particular synaptic mitochondria and lipid metabolism.
Considerable evidence demonstrates that recovery and outcomes after a traumatic brain injury (TBI) are worse in elderly than in younger patients. Moreover, results from our laboratory and others suggest that specific injury mechanisms are altered with age. We believe that mechanism-specific biomarkers visible on proton magnetic resonance spectroscopy (1H-MRS) represent a promising novel approach for elucidating mechanisms of TBI and for translating treatments from preclinical to clinical trials. Our current goal is 1) to determine the magnitude and time course of the metabolic and behavioral effects of TBI in an aged animal model, and 2) determine whether TBI in aged animals is sensitive to neuroprotective treatment with cyclosporine A (CsA).
Robyn Honea, DPhil - KUMC Dept. of Neurology
Chad Slawson, PhD – KUMC Dept. of Biochemistry and Molecular Biology
Complex genetic and environmental mechanisms contribute to late-onset Alzheimer’s disease and the most consistently identified risk factor for AD is family history of dementia. Moreover, maternal transmission of AD is significantly more frequent than paternal transmission. We and others have recently linked maternal transmission of risk for AD to several brain imaging phenotypes. However, the patterns of transmission and biological mechanisms through which a family history of late-onset AD (LOAD) confers risk to offspring are not fully known. There is growing evidence that the mechanism for this maternal inheritance pattern may be related to transmission through mitochondrial DNA (mtDNA) alterations. Our overall goal is to test whether there is a relationship between mitochondrial sequence polymorphisms and imaging markers of risk AD. To do this, we will test for associations between brain imaging endophenotypes and mitochondrial haplogroups derived from138 mitochondrial polymorphisms in two large datasets with imaging, genetic, and behavioral data which, to our knowledge, has never been done.
The objective of this study is to understand function of the O-GlcNAc cycling enzymes during mitochondrial impairment and Alzheimer’s disease progression. This research is driven by the hypothesis that the O-GlcNAc cycling enzymes protect against mitochondrial impairment and that alterations in O-GlcNAc signaling promote Alzheimer’s disease development. Support for this hypothesis comes from past work. A splice variant of O-GlcNAc trsnsferase (OGT) localizes to mitochondria, increased mitochondrial O- GlcNAcylation impairs function and promotes apoptosis. The rationale behind this research is that once we understand the interplay between O-GlcNAcylation and mitochondrial regulation, then we can better understand the biology behind the etiology of Alzheimer’s disease. The regulation of biological processes by O-GlcNAcylation is a novel approach in understanding disease progress. We believe the research proposed in this application is innovative because it will address the involvement of O-GlcNAc signaling in the regulation of Alzheimer’s disease mitochondria.
Research visits are now paperless! We are now using the REDCap system for direct data entry during research visits. Your clinicians will be using a computer to collect research information during study interviews. We appreciate your kindness and patience during this transition. Our memory disorders clinic will be moving to an electronic record system later this fall.
6
Redefining the Baby Boom Generation? not testing experimental drugs, but rather using scans like MRIs to follow normal individuals, people with mild cognitive impairment, and those diagnosed with Alzheimer’s disease to monitor changes in their brains that can lead to clues about how Alzheimer’s disease works. Perhaps no other study has contributed as much to the field of Alzheimer’s disease research as ADNI, but more African Americans need to be represented in this research to reflect the real burden of the disease. Low rates of clinical trial participation are a serious impediment to new discoveries in the field. According to the Alzheimer’s disease research community, the greatest barrier they face is not the disease itself, but finding enough volunteers for studies to progress at the pace needed to develop new treatments as well as a cure.
B
aby boomers may be on the cusp of renaming themselves -- unwillingly. According to a new analysis by the Alzheimer’s Association, Alzheimer’s disease (AD) is quickly becoming “the defining disease of the baby boomers” both because of the millions of boomers who will be afflicted by Alzheimer’s disease, and the millions more who will be caring for someone with the disease. This “Alzheimer’s Generation” is facing some startling statistics.
“If things don’t change soon, Baby Boomers are going to be living with devastating rates of Alzheimer’s disease,” said Dr. Michael Weiner, Primary Investigator of ADNI, a volunteer participant in the study, and caregiver to his mother with Alzheimer’s disease. “But the good news is that they have the numbers and ADNI is currently seeking volunteers to participate in its groundbreaking AD research studies. Anyone between the ages of 55 – 90 who is healthy, diagnosed with Mild Cognitive Impairment or has Alzheimer’s disease, is encouraged to apply. African Americans are urgently needed to participate at any of the 54 research sites across the country that are engaged in ADNI work. The power to drive that change by getting involved in research.”
One in eight baby boomers will get Alzheimer’s disease after they turn 65, and by 2050, the number of Americans with AD will likely reach 13.5 million — and could go as high as 16 million. African Americans, particularly the elderly, are twice as likely to develop the disease than any other demographic … but we don’t know why. In addition, many members of the African American community are often misdiagnosed, and still others go untreated.
With 5.4 million Americans living with AD, chances are that you or someone you know is affected. Perhaps you are one of the 14.9 million caregivers who provide loving, unpaid care to those suffering from the disease. Or maybe you have watched a friend trying to juggle her job, her kids, and taking care of her mom who is getting ever more forgetful. You can help make a difference.
“It is critical for the well-being of the African-American community that we know more about Alzheimer’s disease, and how it affects all populations, including people of color,” said Dr. Karen Bell, Clinical Professor of Neurology at Columbia University and former director of the minority recruitment efforts for the NIA-funded Alzheimer’s Disease Cooperative Study. “We must think about our children and grandchildren, and learn enough now about Alzheimer’s disease to develop treatments or a cure that can make their future brighter than our own.”
“If we all work together and donate our time to studying this disease, we can find the answers we need to potentially change the world as we know it,” said Dr. Bell. “I believe it is possible to stop Alzheimer’s disease in its tracks, but it will take our community coming together, and our nation coming together, to succeed.”
For over 10 years, the Alzheimer’s Disease Neuroimaging Initiative (ADNI) - the largest clinical trial on Alzheimer’s disease in the nation – has been seeking answers about AD. ADNI is helping identify the earliest signs of the disease, when brain damage begins, and when treatments offer the greatest promise for slowing down its progression. ADNI is
To volunteer or to learn more about the study, contact the National Institute on Aging’s Alzheimer’s Disease Education and Referral (ADEAR) Center at (800) 438-4380, or visit www. adni-info.org. 7
ADC News Annual Appreciation Breakfast There were over 164 ADC patients and their families who joined us in celebration of their volunteer efforts on Saturday, March 31st at the Beller Center. Participants and their families received an update on current KU ADC research and enjoyed breakfast catered by Dean & Deluca and served by KU ADC staff. Six individuals won door prizes including a gift-basket from Dean & Deluca and a caregiver devotional written
by TEAM subject Martha Wood. Jami Goodwin received the Karen B. Gregg and Kelly D. Gregg, PhD, Graduate Student Award. Thank you to all who attended and participated.
We bid a fond farewell to:
Arrivals and Departures
• Jami Goodwin, BS, MPA Jami is starting medical school this fall at Washington University in St. Louis. • Pat Laubinger, MPA, BSN Pat is serving as the Coordinator for the NeuroNext Clinical Trial Program • Anita Macan, CCRP, MPA Anita joined the Department of Preventive Medicine as the Project Director for their Education and Training Program • Joe McDonough Research Assitant-TEAM/ADEPT Studies • Cherie Parker, BSN, APRN. Cherie will be joining the Clinical and Translational Science Unit Study Coordinator Pool
Please welcome: • Carrie Randle, MS KU ADC Minority Education Specialist • Becky Bothwell, CCRP Director, KU ADC Clinical Trial Unit • Paul Welch, MPH Research Assitant, KU ADC Clinical Trial Unit • Sally King, MSW, LSCSW LCSW-Outreach and Clinical Education Coordinator • Camille Gray, MPH Clinical Research Coordinator • Sylvie Assa, MC Clinical Research Coordinator
8
Caregiver’s Corner By Phyllis Switzer –– Pick up medications or groceries, someone to stay with your love one while you keep your appointments…..OR…..time ‘for yourself.’ • Keep a section of people who have called to offer help. Never say “NO” but….ask if you could call when something is needed. Remember all of the times you might have called someone and offered support. Give others that same opportunity. Keep track of what happened each day. 1. If medications were taken or if they were skipped 2. Eating changes. What they ate and what they should have had in their diet but didn’t 3. Daily exercise (perhaps taking a walk or exercise tapes). 4. Any aches and pains
A NOTEBOOK …. A JOURNAL …. WHY?
5. Any change in their MOOD, SPEECH, PHYSICAL, and/ or VERBAL COMMENTS
If you are a caregiver, a notebook would be a way to keep track of daily happenings and changes.
6. Problems at night or sleeping more than usual during the day
The more you learn about the disease and keep track of changes, the more confidence you will have in caring for your loved one. Keeping a notebook WILL give you that information.
7. Bowel movements 8. If there was lashing out, consider what happened that day 9. Keep track of what makes them agitated and what works to calm them….. perhaps singing to them, praying with them, playing music, reading to them, etc.
There is so much information you can have when you take the time to write just a couple of sentences EACH DAY.
10. Visitors
It will be so helpful to grab your notebook if you need to take your loved one to the doctor or perhaps to the emergency room. You would be amazed at what information you might forget to mention when you are giving the doctor symptoms or changes.
11. You might write………It was a good day! Check with your doctor as you see issues changing or getting worse. It’s easier for health professionals to help when they know what’s been going on.
It could be a simple, spiral notebook or a three ring binder. Put tabs in your notebook. • Daily happenings
Gratitude
• Medications
Last but not least, write one thing you are grateful for that happened that day.
• Doctor’s names and numbers
Let family members, friends and neighbors know about the journal.
• Past visits to the doctors • List of questions to ask the next time you see the doctor.
If something were to happen to you, all the information needed would be in YOUR notebook.
• Make a section of what your loved one’s needs are and your needs as well
Happy writing!
Dr. Swerdlow, ADC Director, spoke in April at the national gathering of the “Alzheimer’s Association Research Roundtable: Beyond Amyloid symposium,” focusing on non-amyloid causes of AD, titled “Mitochondria: Mechanisms in Neurodegeneration.”
9
Thank You for Your Donations! Thank you to the following donors who contributed to the KU Alzheimer’s Disease Center in 2011. Our research and mission would not be possible without your generosity. John A. Abercrombie & Susan O. Abercrombie Bailey Armstrong Jennie Archer Atwood & Michael D. Atwood, MD Susan L. Aulgur & Steve Aulgur Derek Baron Wanda Bartlett Curtis A. Baum, MD & Paula K. Baum Charles W. Bay Nancy Baylor Willard Bengston & Joyce Bengston Elaine M. Bessier Kimberly S. Bickling & Ryan G. Bickling Judy Clifford Bjorseth Robert E. Bjorseth & Kelly A. Bjorseth Robert J. Bjorseth & Ruth Bjorseth Elsie Blanka Richard D. Blim, MD Stephen J. Bordman & Danielle L. Bordman Jerry Borowick & Karen Borowick William Bosilevac & Linda Bosilevac Janette Mullan Bowen & Scott J. Bowen Keith B. Braman & Karen S. Braman Mary Breed Brink Scott D. Brown Nancy J. Browning & Robert Browning Barbara R. Bryans John A. Buckholtz Wanda R. Buckland Gladys Buller Cecil S. Burdette & Joan K. Burdette Tom Burnham & Mary Burnham Carolyn Burns & Roger Burns *match provided by Sprint Foundation Dennis D. Burns & Ann V. Burns Jeffrey M. Burns, MD & Jennifer Boresow Burns Ann M. Butler Norma D. Cain Betty L. Calcara & Mike L. Calcara John Carr Ray E. Carson & Linda J. Carson Harriett Charno Jason Chrein Edward R. Christophersen, PhD, ABPP & Mildred R. Christophersen Arnie R. Class & Mary S. Class Connie Carson Cleveland Gary Colbern Alan D. Conroy Marlene K. Cook & Roger A. Cook Nancy L. Cooper Anne M. Coveney & Raymond M. Coveney CPDI Team - Per A. Soneson
Creative Care Consultants Barbara J. Cunningham Jerilyn M. Curtiss Delores M. Dalke & John F. Dalke Whitney B. Damron & Kathy Damron Diane Davidner & Dr. Mark Davidner Joleen D. Dibben John B. Dicus & Brenda Roskens Dicus Ruth Dishman & Wayne L. Dishman Teresa M. Druten Joyce Dunn Carleen K. Dvorak Andy Early Neva J. Ebeling Dee Elder & Maxine Elder Glenn Dee Elder Chad Elifrits Betty Ely & Gary L. Ely Gene Ely & Miriam Ely Berniece Ensz Holli D. Ensz Marilyn R. Ensz & Willis D. Ensz Norman Ensz & Dorothy Ensz Yvonne D. Ensz & Leo W. Ensz Faith Connections Julia Ferguson & Al Ferguson Ralph Fine Sandra Floyd Susan Floyd & Mike Floyd Susan Murray Foley & Kevin M. Foley Nancy A. Friesen David Gaston & Elizabeth S. Gaston Connie J. Gentz Jeanette L. Gerlach & George Gerlach Jerry Ginden & Helene Ginden Guy Giroux & Lisa Giroux Cliff Gordon Gottlieb, Flekier & Company Kelly D. Gregg, PhD & Karen B. Gregg Candy Hall Joe L. Handlos & Jane M. Handlos James R. Hanni F. Marvelle Harris Jerry R. Hartley & Kay Hartley Cora R. Hawkinson Carol J. Herbig Bradley J. Herzet Jacque Herzet & Max L. Herzet Sandra R. Herzet Marcia K. Higginson The Hon. Don A. Hill & Robbie G. Hill Kathryn R. Holder & Thomas M. Holder, MD Beverly Holdren Gene R. Hotchkiss & Kari Hotchkiss Nancy L. Hubbard & John E. Hubbard Connie Hubbell & Patrick R. Hubbell 10
C. Meade Hubby Henry H. Hyndman, Jr. & Janet Hyndman *match provided by Boeing Corporation Shelly Ingram Lori Bjorseth Inman & Peter B. Inman Almetta Iverson Charlene A. Janzen Jayhawk Club #1 - Roger & Linda McCauley June E. Johnson Marilyn K. Johnson Wendy Wauson Johnson Glenda K. Jones Lane A. Jones Renay Jones Ken Judd & Wendy B. Judd Junction City Middle School Kay Kaiser Kansas Foundation for Medical Care, Inc. Kay Kennedy R. Arlen Kirkwood & Darlene Kirkwood Harold H. Kneisel & Louise L. Kneisel Jack L. Knight & Linda M. Knight Bill Koehn & Gloria Koehn Audrey H. Langworthy & A. C. Langworthy Jr. Mary C. Lathrop Carla J. Lee Dorothy E. Letellier & Richard D. Letellier Celeste A. Lindell Thomas C. Lohrenz & Lori L. Lohrenz Robert R. Lohse Jr., DDS & Kathy J. Lohse Carolyn T. Long Ann K. Ludwig Bea E. Ludwig Erin M. Ludwig, R.N. Linda E. Lungstrum & John W. Lungstrum Janet L. Lunn & Phillip F. Lunn Jan Maddox Robert Malone John F. Marshall & Kaye E. Marshall Eugene Marten & Grace Marten Medicap Pharmacy Joyce A. Meehan Emily Meissen-Sebelius Lela E. Melson Angela C. Messer Mary H. Meyer Juliana Michalski & Michael J. Michalski Patricia J. Miller Peggy Miller
Kenneth C. Mishler, PharmD & Debbie Ensz Mishler John E. Moenius Jr. & Chandler Hayes Moenius Monday Night Football co-workers & friends - Robert W. Gray Clayton E. Moon Ron Moon Janice Morris Betty L. Murray Carol Murray & Ted Murray Dr. F. Roger Murray Elizabeth M. Napoli Marilyn S. Newton Alicia J. Nolte & Jerry M. Nolte Robert R. Payne, MD & Doris Kendall Payne Jayne M. Pearson Pediatric Associates Zachary C. Peek Debbie K. Peterson-Luttrell John D. Pinegar Prescription Solutions Kurt Reiber William Reynolds Evelyn Rhoades Rebecca S. Rhoades Marily Harper Rhudy David W. Richards Helen L. Robinson & Jack W. Robinson Richard D. Ross Janet L. Roth & Philip R. Roth Patricia D. Rumbaugh Estella Marie Schmidt Jim Schmidt & Sue Schmidt Michael J. Schmidt, MD & The Hon. Vicki L. Schmidt Robert A. Schmidt & Christina W. Schmidt
Everett E. Schnitzler Mary S. Schrandt Linda Schuck Kenneth A. Schwartz, MD Virginia Aeschleman Schwartz Schwerdt Design Group, Inc. Blayne V. Scofield Candace M. Scott & Loren E. Scott Pamela Sue Scott Lindsey Bjorseth Serrano Joseph D. Serrano Jobelle Anderson Shands Jeanne Whyte Shopen & Helen M. Simpler Debbie Simpson Brenda L. Sinks Douglas E. Smith William W. Sneed Matthew A. Speise Joe E. Spurney, MD & Cozette Chappell Spurney St. Joseph Ladies Guild Robert F. St. Peter, MD & Anne D. St. Peter Sharon Stead Jack Stelmach, MD & Patricia A. Stelmach Marilyn J. Stephen & Alan C. Stephen Vernon Stephens & Kay Stephens B. Jo Lynn Stout J. B. Stuckey & Louise Stuckey Elizabeth F. Swanson-Hyland & Charles J. Hyland Tallgrass Surgical Center Dr. Stanley M. Teeter & Jo Anne Teeter TelecomPioneers Kathy Thissen Victoria Thomas, JD & Roger O. Lambson, PhD
Frank L. Thompson & Evangeline A. Thompson L. Thompson Dennis D. Tietze, MD & The Hon. Anna M. Tietze Marsha Williams Tinkum Jennifer D. Trimble Paul D. Uhlmansiek & Joycelyn A. Uhlmansiek Michael L. Unruh & Trudy I. Unruh Rosalie A. Vanzant Lora Kelller Viets & Michael E. Viets Katharyn L. Volland Kathy Voth Kathy Waddell Stanford Weinberg & Toby Weinberg Jerry S. Weis, PhD & Linda B. Weis Thomas J. Wesoloski & Teresa L. Wesoloski Richard A. White & Margaret M. White Jack L. Williams & Claire Williams Carla J. Williamson James H. Williamson & Marilyn B. Williamson Larry P. Wills & Doris A. Wills Susan M. Wilson Barbara L. Wood & Robert M. Wood, DDS Edward R. Wood, MD Bridget G. Wood Mary L. Woodall W. Joel Wurster, MD & Patricia A. Wurster Leslie A. Yelick Dean K. Zellers & Marilyn G. Zellers Susan Zimmerman Nancy G. Zogleman Helen A. Zuber & Arvid Zuber
Find Us on Facebook and Twitter! Follow us on Twitter: @KUALZ www.twitter.com/KUALZ
“Like” the University of Kansas Alzheimer’s Disease Center on Facebook by using this link: http://www.facebook.com/KUADC
11
Upcoming Events: Seminar Series on Aging, Health & Dementia Landon Center on Aging, Room 270, 12:00 p.m. - 1:00 p.m. Free lunch to the first 15 attendees. September 11, 2014 October 9, 2014 November 13, 2014 Life Review Neuroprotecting Drug Target Insulin and Alzheimer’s Disease Tom Meuser, PhD Discovery & Therapy Development Jill Morris, Post-doctoral fellow Peter Koulen, PhD September 25, 2014 October 30, 2014 November 27, 2014 Navigating the Environment The Latest Grief Research Alzheimer’s Disease Brain Pathology Shawn Parcells, FPA Stephen Bonasera, MD, PhD Sally King, MSW, LSCSW, LCSW, RYT Alzheimer & Memory Program Caregiver Support Group 2:00-3:30 p.m., Landon Center on Aging, Room 145 (Second Thursday of Each Month) September 13 • October 11 • November 8 Down Syndrome Dementia Clinic (DSDC) Afternoons, Landon Center on Aging Clinic (First Thursday of Each Month) To schedule an appointment, please call 913-588-6820 September 6 • October 4 • November 1
If you wish to receive this newsletter electronically, please submit your name and e-mail address to us at KUAMP@kumc.edu
www.kualzheimer.org
Visit Us Online!!!
Phone: (913) 588-0555 Fax: (913) 945-5035 E-mail: KUAMP@kumc.edu
Contact Information Department of Neurology Mail Stop 1063 2100 W. 36th Avenue Kansas City, KS 66160